Liver disease research funding
Jay H. Hoofnagle – 30 January 2004
Jay H. Hoofnagle – 30 January 2004
Daniel Jaeck, Philippe Bachellier, Elie Oussoultzoglou, Jean‐Christophe Weber, Philippe Wolf – 30 January 2004 – A multicenter retrospective review of 1467 patients treated by liver resection (LR) for hepatocellular carcinoma (HCC) in Europe over a 13‐year period showed a mean mortality rate of 10.6%, which was correlated with the extent of LR, the etiology of cirrhosis and the study period with an improvement during the last years. Improved 5‐year overall survival (20–51%) and disease‐free survival (20–33%) reached similar rates in cirrhotic than in non‐cirrhotic patients.
Guido Torzilli, Natale Olivari, Daniele Del Fabbro, Piera Leoni, Adele Gendarini, Angela Palmisano, Marco Montorsi, Masatoshi Makuuchi – 30 January 2004 – Fine‐needle biopsy (FNB) is associated with problems, such as tumor seeding, which are not negligible. The aim of this study was to validate prospectively the accuracy of our diagnostic work‐up without FNB, not just to address but also to rule out from a surgical program patients with focal liver lesions (FLLs). From September 2001 to July 2003, 89 patients were seen at an outpatient clinic for FLLs.
Mark C. Bellamy, Jacqui A. Gedney, Helen Buglass, Jimmy H.C. Gooi, on behalf of the Leeds Liver Group – 30 January 2004 – Hemodynamic changes and elevation of intracellular calcium following reperfusion in human liver transplantation occur rapidly and do not match the time course of cytokine expression, therefore, we postulate involvement of other, pre‐formed substances, such as complement. We studied 40 adult patients undergoing liver transplantation.
30 January 2004
Nicholas Murphy, Georg Auzinger, William Bernel, Julia Wendon – 30 January 2004 – Acute liver failure (ALF) is a rare condition characterized by the development of encephalopathy in the absence of chronic liver disease. Cerebral edema occurs in up to 80% of patients with Grade IV encephalopathy. In the current prospective randomized controlled clinical trial, we examined the effect of induced hypernatremia on the incidence of intracranial hypertension (IH) in patients with ALF. Thirty patients with ALF and Grade III or IV encephalopathy were randomized.
Ulrich A. Walker, Jochen Bäuerle, Montse Laguno, Javier Murillas, Stefan Mauss, Günther Schmutz, Bernhard Setzer, Rosa Miquel, José M. Gatell, Josep Mallolas – 30 January 2004 – The “D drug” HIV reverse‐transcriptase inhibitors zalcitabine, didanosine, and stavudine are relatively strong inhibitors of polymerase‐gamma compared with the “non–D drugs” zidovudine, lamivudine, and abacavir. D drugs deplete mitochondrial DNA (mtDNA) in cultured hepatocytes. This mtDNA depletion is associated with an increased in vitro production of lactate.
Arndt Vogel, Inge E.T. van den Berg, Muhsen Al‐Dhalimy, John Groopman, Ching‐Nan Ou, Olga Ryabinina, Mihail S. Iordanov, Milton Finegold, Markus Grompe – 30 January 2004 – The murine model of hereditary tyrosinemia type 1 (HT1) was used to analyze the relationship between chronic liver disease and programmed cell death in vivo. In healthy fumarylacetoacetate hydrolase deficient mice (Fah‐/‐), protected from liver injury by the drug 2‐(2‐ nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC), the tyrosine metabolite homogentisic acid (HGA) caused rapid hepatocyte death.
Maria H Sjogren – 30 January 2004
Jean M. Regimbeau, Magali Colombat, Philippe Mognol, François Durand, Eddie Abdalla, Claude Degott, Françoise Degos, Olivier Farges, Jacques Belghiti – 30 January 2004 – Ten percent of patients who undergo resection for hepatocellular carcinoma (HCC) associated with chronic liver disease have no detectable cause for this underlying liver disease. Recent studies have shown that patients with cryptogenic chronic liver disease frequently have risk factors for nonalcoholic fatty liver disease (NAFLD).